Skip to content
The Policy VaultThe Policy Vault

Tasigna — CareFirst (Caremark)

Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS/TGCT)

Initial criteria

  • Requested medication used as a single agent for treatment of PVNS or TGCT

Reauthorization criteria

  • No evidence of unacceptable toxicity or disease progression while on current regimen

Approval duration

Initial 12 months; Reauthorization 12 months